TRASTUZUMAB DERUXTECAN

Brand name:

• Enhertu®

Pharmaceutical company:

Astrazeneca Pty Ltd

Condition/indication:
(therapeutic use)

• Human epidermal growth factor receptor 2 (HER2)-low breast cancer

PBAC Submission type:

New listing (Category 1)

Comment:

--

Public Summary Document:

PBAC Public Summary Documents – November 2023

Related medicines:

--

Submission received for:

November 2023 PBAC meeting

Opportunity for consumer comment:

Open 26/07/2023 and close 20/09/2023 (see PBS Website)

PBAC meeting:

Held on 01/11/2023

PBAC outcome published:

Not Recommended (see PBAC Outcomes)

5Lodgement of required documentation:

Has not yet commenced

6Agreement to listing arrangements:

Has not yet commenced

7Government processes:

Has not yet commenced

8Medicine listed on the PBS:

Has not yet occurred

---